Tag Archives: cabazitaxel

New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy!   An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , , , , , , , , , | Comments Off on New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

New Prostate Cancer Drug Approved by FDA

Good news for patients with metastatic prostate cancer.  The FDA (US Food and Drug Administration) has approved Johnson & Johnson’s Zytiga (abiraterone) in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy.  Abiraterone … Continue reading

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , | 1 Comment

New Chemotherapy, Cabazitaxel (Jevtana), for Advanced Prostate Cancer

A new chemotherapy, Cabazitaxel (Jevtana) has been approved in the United States to treat men who have advanced hormone-refractory prostate cancer and have failed docetaxel. The approval was based on the results of the phase 3 TROPIC clinical study, which … Continue reading

Posted in Cancer, Prostate cancer | Tagged , , , , , , , | Comments Off on New Chemotherapy, Cabazitaxel (Jevtana), for Advanced Prostate Cancer